Literature DB >> 30983353

Mass Spectrometry-Based Quantification of Tau in Human Cerebrospinal Fluid Using a Complementary Tryptic Peptide Standard.

Maotian Zhou, Duc M Duong, Erik C B Johnson, Jingting Dai1, James J Lah, Allan I Levey, Nicholas T Seyfried.   

Abstract

Here, we report a method for the generation of complementary tryptic (CompTryp) isotope-labeled peptide standards for the relative and absolute quantification of proteins by mass spectrometry (MS). These standards can be digested in parallel with either trypsin (Tryp-C) or trypsin-N (Tryp-N), to generate peptides that significantly overlap in primary sequence having C- and N-terminal arginine and lysine residues, respectively. As a proof of concept, an isotope-labeled CompTryp standard was synthesized for Tau, a well-established biomarker in Alzheimer's disease (AD), which included both N- and C-terminal heavy isotope-labeled (15N and 13C) arginine residues and flanking amino acid sequences to monitor proteolytic digestion. Despite having the exact same mass, the N- and C-terminal heavy Tau peptides are distinguishable by retention time and MS/MS fragmentation profiles. The isotope-labeled Tau CompTryp standard was added to human cerebrospinal fluid (CSF) followed by parallel digestion with Tryp-N and Tryp-C. The native and isotope-labeled peptide pairs were quantified by parallel reaction monitoring (PRM) in a single assay. Notably, both tryptic peptides were effective at quantifying Tau in human CSF, and both showed a significant difference in CSF Tau levels between AD and controls. Treating these CompTryp Tau peptide measurements as independent replicates also improved the coefficient of variation and correlation with Tau immunoassays. More broadly, we propose that CompTryp standards can be generated for any protein of interest, providing an efficient method to improve the robustness and reproducibility for MS analysis of clinical and research samples.

Entities:  

Keywords:  Alzheimer’s disease (AD); biomarker; neurodegeneration; parallel reaction monitoring (PRM); proteomics

Mesh:

Substances:

Year:  2019        PMID: 30983353     DOI: 10.1021/acs.jproteome.8b00920

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   5.370


  5 in total

1.  Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease.

Authors:  Lenora Higginbotham; Lingyan Ping; Eric B Dammer; Duc M Duong; Maotian Zhou; Marla Gearing; Cheyenne Hurst; Jonathan D Glass; Stewart A Factor; Erik C B Johnson; Ihab Hajjar; James J Lah; Allan I Levey; Nicholas T Seyfried
Journal:  Sci Adv       Date:  2020-10-21       Impact factor: 14.136

2.  An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS/MS.

Authors:  Wade Self; Khader Awwad; John Paul Savaryn; Michael Schulz
Journal:  PLoS One       Date:  2022-06-02       Impact factor: 3.752

3.  Targeted Quantification of Detergent-Insoluble RNA-Binding Proteins in Human Brain Reveals Stage and Disease Specific Co-aggregation in Alzheimer's Disease.

Authors:  Qi Guo; Eric B Dammer; Maotian Zhou; Sean R Kundinger; Marla Gearing; James J Lah; Allan I Levey; Joshua M Shulman; Nicholas T Seyfried
Journal:  Front Mol Neurosci       Date:  2021-03-18       Impact factor: 5.639

4.  Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer's disease.

Authors:  Maotian Zhou; Rafi U Haque; Eric B Dammer; Duc M Duong; Lingyan Ping; Erik C B Johnson; James J Lah; Allan I Levey; Nicholas T Seyfried
Journal:  Clin Proteomics       Date:  2020-05-29       Impact factor: 3.988

Review 5.  Proteomics Landscape of Alzheimer's Disease.

Authors:  Ankit P Jain; Gajanan Sathe
Journal:  Proteomes       Date:  2021-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.